…The most recent results from the SIMCOMBIN trial of combined beta-interferon and simvastatin, an HMG CoA reductase inhibitor, indicate that there is no beneficial effect with add-on therapy (Sorensen et al. Lancet Neurol 2011; 10: 691-701). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
A number of early reports suggested that the risk of AD was reduced in patients taking an HMG CoA reductase inhibitor (statin) (Wolozin et al. Arch Neurol 2000; 57: 1439-1443, free full text at http://archneur.ama-assn.org/cgi/reprint/57/10/1439; Rockwood et al. Arch Neurol 2002; 59: 223-227, free full text at http://archneur.ama-assn.org/cgi/reprint/59/2/223). Subscribe to read more It takes 30 seconds or login using your email address Please en…
….S. and Europe. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – Data from phase II extension studies of fingolimod and teriflunomide indicate that long-term treatment with an oral MS therapy appears safe, with no new safety signals during the observation period. Subscribe to read more It takes 30 seconds or login using your email address Please…
REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – Two studies targeting B cells report mixed results – one positive, the other negative – in the treatment of MS, suggesting that there may be hidden challenges for this novel therapeutic approach. Subscribe to read more It takes 30 seconds or login using your email address Please ent…